I've been in this company for over a year now so I'd think
I've been in this company for over a year now so I'd think that would qualify me as an investor not a flipper. That being said, I'm pissed at the company. Their continued silence is bullshit.
1.) The company stated not some random poster its intent to cross-list. Six months later crickets...
2.) A company official stated results from the cream study would be out very soon... Again over six months later crickets...
3.) Last year's presentation was an epic failure. I know they're very smart people involved - Dr. Hirsch cannot go into the presentation and regurgitate the same information that's already on the investor powerpoint and think that will generate any additional investment / interest from those in attendance. They better have something big in the works to announce otherwise they will have pissed away another $100K.
4.) The last 8K stated update early 2018... of course that's vague so there's some leeway with that one, but tick, tock - most people would probably say the end of January is no longer early 2018.
5.) Dr. Hirsch cannot go into the presentation with the share price bleeding red. I contend anything below $1.00 is probably looked upon by the fund managers as get real - come back and see us again when you're ready to be taken seriously. I was really hoping for a $1.00 base going into the conference but that now appears to be a long shot.
6.) The new director showing on the WSJ page - it's very simple. Either we have a new director or not. Let's get the easy stuff done right for once.
I'm not in the camp of thinking my account will go to millionaire status overnight based on some grand reveal, but my expectations are to see continued progress... not constant decline like we experienced in 2017.
I appreciate your insights and optimism, but I also understand the frustrations many have with OWCP management. I can only hope those attending the conference will ask tough but fair questions of the OWCP team in attendance and don't let him get away with evasive answers. GLTA
7
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue Reading
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...
Continue Reading
Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...
Continue Reading
Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...
Continue Reading
A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...
Continue Reading
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
Top 5 Most Recently Viewed Articles
Old National Bancorp Declares Cash Dividends Old National Bancorp, the holding company of Old National Bank, has recently made an important announcement regarding its quarterly dividends. The Board of Directors has officially declared a cash dividend of $0.14 per share on the Company’s outstanding shares of common stock. This move underlines the company’s commitment...
Continue Reading
Innovative Design for Axe Throwing Enthusiasts A new invention is transforming the world of axe throwing. A creative inventor sought to develop a robust solution for supporting heavy wooden targets. With this ambition in mind, he has introduced the AXXMAN BOARD, which enhances the experience of axe throwing while also ensuring safety and stability. This product aims to...
Continue Reading
AI Innovations Transforming Automotive Lighting Market Growth The global automotive lighting market is poised for remarkable growth, with an expected increase of approximately USD 12.38 billion between 2024 and 2028. This growth is largely driven by the rising demand for advanced interior lighting systems, particularly in passenger and commercial vehicles. The advent of...
Continue Reading
Wolverine World Wide Insider Purchase Signals Optimism In a recent filing, it has come to light that DeMonty Price, a board member of Wolverine World Wide (NYSE:WWW), made a significant insider purchase, affirming confidence in the future of the company. Details of the Transaction On a recent date, Price purchased 25,000 shares of Wolverine World Wide. This strategic move...
Continue Reading
Saigon Technology's Impact on Vietnam's Global Innovation Scene Saigon Technology is making waves in the tech world, showcasing Vietnam's potential as a vibrant hub for global innovation. This remarkable company has recently achieved significant milestones that solidify its position in the industry. With its unyielding commitment to excellence, Saigon Technology has...
Continue Reading
